Loading...
Market
Which country will be first to approve RYBREVANT® and LAZCLUZE™ outside the US by August 2025?
2
Resolution / Starting Odds
European Union • 25%
Canada • 25%
Japan • 25%
Other • 25%
Approval announcements from respective country’s health regulatory agencies
Story
FDA Approves J&J's RYBREVANT® and LAZCLUZE™ for EGFR-Mutated Lung Cancer
Aug 20, 2024, 11:18 AM
The U.S. Food and Drug Administration (FDA) has granted approval to Johnson & Johnson's chemotherapy-free combination therapy for treating a specific type of non-small cell lung cancer. The treatment, which includes RYBREVANT® (amivantamab-vmjw) and LAZCLUZE™ (lazertinib), is designed as a first-line option for patients with EGFR-mutated advanced lung cancer. This marks Johnson & Johnson's first FDA approval for a chemotherapy-free lung cancer treatment.
View original story
Similar markets
Japan • 25%
Canada • 25%
Australia • 25%
None of the above • 25%
Less than 10 • 25%
10-20 • 25%
21-30 • 25%
More than 30 • 25%
Lung cancer related indication • 25%
Other cancer indication • 25%
Non-cancer indication • 25%
No new approval • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Yes • 50%
No • 50%
Canada • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
European Union • 25%
Other • 25%
India • 25%
South Africa • 25%
Brazil • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Australia • 25%
Other • 25%